Kromatid
LONGMONT, CO · Biotechnology, Other · 36 employees
KromaTiD supports research teams in academia, large pharmaceutical, and therapeutic companies with expert scientific support and unparalleled genomics tools and services. We are your partner for biomarker discovery, genotoxicity studies, clone screening assessment of editing-associated errors, and plasmid manufacturing.
Funding history
- Seed — $3.6M — Jul 2025
- Seed — $3.5M — Jul 2025
- Seed — $2.1M — Jan 2024
- Venture - Series Unknown — $7.9M — Oct 2021
- Seed — $3.6M — Jan 2017
Recent signals
- Jun 18, 2026: KROMATID Appoints Matthew Hemstreet as Chief Executive Officer
- Jul 10, 2025: Raised $3.6M in Seed
- Jul 10, 2025: Raised $3.5M in Seed
- Jan 31, 2024: Raised $2.1M in Seed
- Oct 15, 2021: Raised $7.9M in Venture - Series Unknown
- Jan 26, 2017: Raised $3.6M in Seed
See plans & pricing → Track Kromatid’s funding, hiring, and signals — with verified contacts — on Fundz.